NCT07227064PHASE3Recruiting
Methadone in THA for Post-op Pain and Opioid Reduction
Medical University of South Carolina
Start Date
1/12/2026
Completion Date
1/31/2027
Summary
This randomized, double-blind controlled trial investigates whether intraoperative intravenous methadone (0.15 mg/kg based on ideal body weight) reduces acute postoperative pain and opioid consumption in patients undergoing elective total hip arthroplasty under spinal anesthesia with mepivacaine. The primary outcome is patient-reported pain on a visual analog scale (VAS) 30-60 minutes after arrival in the post-anesthesia care unit (PACU). Secondary outcomes include opioid use, pain scores over time, incidence of nausea/vomiting, and quality of recovery. A total of 162 subjects will be enrolled at MUSC surgical sites.
Eligibility Criteria
Age Range: 18 years to 75 years
Inclusion
* Ages 18-75 years of age
* Undergoing elective primary total hip arthroplasty with mepivacaine in the spinal anesthesia
Exclusion
* Allergy to methadone or mepivacaine
* Severe liver disease defined as Child's Pugh Class C
* End stage renal disease requiring dialysis
* Known diagnosis of prolonged QT syndrome
* Currently pregnant
* Unable to provide written, informed consent
* Non-English speaking
Interventions
DRUG
Methadone
Conditions
Post Operative PainTotal Hip Arthroplasty
Locations
Medical University of South Carolina
Charleston, South Carolina 29425
United States